文献速递泌尿生殖与妇科肿瘤放疗

日本复发性妇科癌症再程放疗采用高剂量率近距离治疗:一项关于实践模式与结局的多中心调查

Reirradiation for recurrent gynecologic cancer using high-dose-rate brachytherapy in Japan: A multicenter survey on practice patterns and outcomes.
PubMed 文献 · Radiother Oncol · 2024-04-05

该回顾性多中心图表审查纳入2000至2018年9家机构165例接受高剂量率近距离再程放疗的复发性妇科癌症患者,其中142例以治愈为目的分析。宫颈癌3年总生存率53%、无进展生存率44%、局部控制率61%;子宫内膜癌分别为100%、64%、70%;外阴及阴道癌分别为54%、38%、43%。再程放疗间隔<1年和肿瘤体积≥25 cm³为不良预后因素,30%患者出现≥3级晚期毒性。

要点

  • 再程放疗间隔<1年是总生存、无进展生存和局部控制的显著危险因素。
  • 肿瘤体积≥25 cm³是总生存的显著危险因素。
  • 165例中49例(30%)发生≥3级晚期毒性,累积EQD2(α/β=3)较高与严重并发症显著相关。

核心结论

  • 高剂量率近距离再程放疗对复发性妇科癌症有效,尤其在再程放疗间隔较长的病例中。

研究设计与样本

  • 回顾性多中心图表审查,纳入2000至2018年日本9家机构的165例接受高剂量率近距离再程放疗的复发性妇科癌症患者。
  • 结局分析纳入142例以治愈为目的治疗的患者,幸存者中位随访30个月(范围1-130个月)。

主要发现

  • 宫颈癌3年总生存率53%(95%CI:42-63%)、无进展生存率44%(35-53%)、局部控制率61%(50-70%)。
  • 子宫内膜癌3年总生存率100%(NA)、无进展生存率64%(30-85%)、局部控制率70%(32-89%)。
  • 外阴及阴道癌3年总生存率54%(13-83%)、无进展生存率38%(6-72%)、局部控制率43%(6-78%)。
  • 多因素分析中,再程放疗间隔<1年是总生存、无进展生存和局部控制的显著危险因素;肿瘤体积≥25 cm³是总生存的显著危险因素。
  • 全部165例中49例(30%)发生≥3级晚期毒性,累积EQD2(α/β=3)较高与严重并发症显著相关。

临床怎么用

  • 原文结论认为高剂量率近距离再程放疗对复发性妇科癌症有效,尤其在再程放疗间隔较长的病例中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The aim of the study is to examine the present status of reirradiation with high-dose-rate (HDR) brachytherapy for recurrent gynecologic cancer in Japan and to determine the role of this therapy in clinical practice. MATERIALS AND METHODS: A retrospective multicenter chart review was performed for reirradiation for gynecologic cancer using HDR brachytherapy. Each center provided information on patient characteristics, treatment outcomes, and complications. RESULTS: The study included 165 patients treated at 9 facilities from 2000 to 2018. The analysis of outcomes included 142 patients treated with curative intent. The median follow-up time for survivors was 30 months (range 1-130 months). The 3-year overall survival (OS), progression-free survival (PFS), and local control (LC) rates were 53 % (95 %CI: 42-63 %), 44 % (35-53 %), and 61 % (50-70 %) for cervical cancer; 100 % (NA), 64 % (30-85 %), and 70 % (32-89 %) for endometrial cancer; and 54 % (13-83 %), 38 % (6-72 %), and 43 % (6-78 %) for vulvar and vaginal cancer, respectively. In multivariate analysis, interval to reirradiation (<1 year) was a significant risk factor for OS, PFS and LC; Gross Tumor Volume (≥25 cm3) was a significant risk factor for OS. Toxicities were analyzed in all enrolled patients (n = 165). Grade ≥ 3 late toxicities occurred in 49 patients (30 %). A higher cumulative EQD2 (α/β = 3) was significantly associated with severe complications. CONCLUSION: Reirradiation with HDR brachytherapy for recurrent gynecologic cancer is effective, especially in cases with a long interval before reirradiation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Isohashi F, Yoshida K, Murakami N, et al. Reirradiation for recurrent gynecologic cancer using high-dose-rate brachytherapy in Japan: A multicenter survey on practice patterns and outcomes. Radiother Oncol. 2024. PMID: 38583719. doi:10.1016/j.radonc.2024.110269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。